Trial design of phase IIIb, open-label, single arm study to evaluate efficacy and safety of pasireotide LAR in patients with inadequately-controlled acromegaly despite treatment with first-generation somatostatin analogues
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.